Emerging Trends to Drive Ovarian Cancer Diagnostics Market Growth at 7.6% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Ovarian Cancer Diagnostics Market Size Growth Forecast: What to Expect by 2025?
The market size for ovarian cancer diagnostics has seen a robust increase in recent years. The growth is projected from $2.74 billion in 2024 to $2.9 billion in 2025 with a compound annual growth rate (CAGR) of 5.7%. Factors contributing to this growth during the historical span include advancements in biomarker discovery and validation, increased use of transvaginal ultrasound, raised awareness about BRCA gene mutations, extensive research on tumor markers, and the implementation of screening programs and guidelines.

How Will the Ovarian Cancer Diagnostics Market Size Evolve and Grow by 2029?
The market for ovarian cancer diagnostics is projected to witness considerable growth over the coming years, with an expected valuation of $3.88 billion in 2029, growing at a Compound Annual Growth Rate (CAGR) of 7.6%. This growth during the forecast period is mainly due to the emphasis on early detection initiatives, a rising number of ovarian cancer cases, the incorporation of artificial intelligence (AI), tailoring of medicine approaches, the emergence of new biomarkers, as well as genomic and proteomic profiling. The forecast period also sees significant trends such as the use of biosensor technologies for early detection, integrating digital pathology, breakthroughs in imaging modalities, enhanced imaging technologies, and progressive techniques in pathology.

View the full report here:
https://www.thebusinessresearchcompany.com/report/ovarian-cancer-diagnostics-global-market-report

What Drivers Are Propelling the Growth of Ovarian Cancer Diagnostics Market Forward?
The increase in instances of ovarian cancer is anticipated to fuel the expansion of the market for ovarian cancer diagnostics. Ovarian cancer is a harmful tumor that forms in the ovaries, which are the female reproductive organs that produce eggs and hormones. The surge is linked to higher life expectancy, later childbirth, and lifestyle modifications. By facilitating early recognition and intervention, ovarian cancer diagnostics could decrease the rate of ovarian cancer, leading to immediate treatment and better results. For example, the World Ovarian Cancer, a Canadian organization dedicated to heightening global awareness among women affected by ovarian cancer, anticipates that by 2050, global occurrences of ovarian cancer amongst women will rise by over 55%, amounting to about 503,448 cases. Also, the yearly mortality rate from ovarian cancer is foreseen to increase to 350,956, demonstrating nearly a 70% rise from 2022. Thus, the growing prevalence of ovarian cancer is triggering the expansion of the ovarian cancer diagnostic market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12022&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Ovarian Cancer Diagnostics Market?
The uptake of advanced diagnostic technology is a prominent trend in the ovarian cancer diagnostics market. Firms in this market are leveraging sophisticated diagnostic technology to maintain their market standing. As an illustration, in November 2022, Hoffmann-La Roche AG, a Switzerland-based pharmaceutical and healthcare corporation, won FDA approval for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This is the first-ever (immunohistochemistry) IHC-based companion diagnostic test approached for determining the appropriateness of ovarian cancer patients for ELAHERE, a prescribed ovarian cancer drug. The design of this test is particularly meant to gather crucial knowledge and comprehensive clinical data about the state of ovarian cancer. Furthermore, it helps augment disease control and patient outcomes.

What Are the Key Segments in the Ovarian Cancer Diagnostics Market?
The ovarian cancer diagnostics market covered in this report is segmented -

1) By Product Type: Instruments, Kits, Reagents
2) By Diagnosis Type: Biopsy, Blood Test, Imaging, Other Diagnosis Types
3) By Cancer Type: Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Other Cancer Types
4) By End User: Cancer Diagnostic Centers, Hospital Laboratories, Research Institutes

Subsegments:
1) By Instruments: Imaging Systems, Biopsy Devices, Molecular Diagnostic Instruments
2) By Kits: Diagnostic Test Kits, Screening Kits
3) By Reagents: Antibodies, Enzymes, Assay Reagents

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12022&type=smp

Who Are the Key Players Shaping the Ovarian Cancer Diagnostics Market's Competitive Landscape?
Major companies operating in the ovarian cancer diagnostics market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Bio-rad Laboratories Inc., Qiagen N.V., Natera Inc., Myriad Genetics Inc., ArcherDX Inc., Invitae Corporation, Guardant Health, Luminex Corporation, NanoString Technologies Inc., Siemens Healthcare Private Limited, Menarini Silicon Biosystems S.p.A., Precipio Inc., Angle plc

What Geographic Markets Are Powering Growth in the Ovarian Cancer Diagnostics Market?
North America was the largest region in the ovarian cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ovarian cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12022

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.